Articles Referencing NVO
Positive Data on Novartis' Jakavi - Analyst Blog
6/18/2013, 5:30 pm from Zacks.com in Investing, Business, Stocks
Novartis ( NVS ) recently
presented positive results on oncology drug Jakavi from a
three-year follow up analysis of a phase III trial, COMFORT
II.
It was observed that the overall... Read >>
J&J to Buy Aragon for $1 Billion - Analyst Blog
6/18/2013, 11:30 am from Zacks.com in Investing, Business, Stocks
With the intention of strengthening its prostate cancer
portfolio, Johnson & Johnson ( JNJ ) recently
announced its intention to acquire privately-held, pharmaceutical
discovery and... Read >>
Lilly Alzheimer's Study Terminated - Analyst Blog
6/14/2013, 11:30 am from Zacks.com in Investing, Business, Stocks
Eli Lilly and Company ( LLY ) recently
announced the voluntary termination of a mid-stage study being
conducted with its Alzheimer's disease candidate, LY2886721.
LY2886721, a beta... Read >>
Sanofi's Fluzone Quadrivalent Gets FDA Nod - Analyst Blog
6/13/2013, 11:30 am from Zacks.com in Investing, Business, Stocks
Sanofi ( SNY ) recently
announced that the US Food and Drug Administration (FDA) has
cleared its quadrivalent formulation of Fluzone. The four-strain
influenza vaccine has been approved for... Read >>
CHMP Positive on Sanofi's Lantus - Analyst Blog
6/11/2013, 6:13 pm from Zacks.com in Investing, Business, Stocks
The Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) recently issued a positive opinion
related to Sanofi 's ( SNY ) diabetes drug,
Lantus.... Read >>
FDA Panel Positive on GSK's Avandia - Analyst Blog
6/7/2013, 5:29 pm from Zacks.com in Investing, Business, Stocks
Good news recently flowed in at GlaxoSmithKline
( GSK ) when the
joint advisory committee (comprising Endocrinologic and Metabolic
Drugs Advisory Committee and the Drug Safety and Risk... Read >>
Novo Nordisk Seeks IDegLira Approval - Analyst Blog
6/3/2013, 6:29 pm from Zacks.com in Investing, Business, Stocks
Novo Nordisk ( NVO ) recently
submitted marketing applications to the European Medicines Agency
(EMA) seeking approval for its type II diabetes candidate,
IDegLira. IDegLira is the... Read >>
Encouraging Data from Novartis - Analyst Blog
5/29/2013, 4:31 pm from Zacks.com in Investing, Business, Stocks
Novartis ( NVS ) recently
announced encouraging data on diabetes drug Galvus (vildagliptin)
from a large multi-center randomized trial, INTERVAL study
(n=278). The 24-week study... Read >>
Encouraging Data from Novartis - Analyst Blog
5/29/2013, 12:25 pm from Zacks.com in Investing, Business, Stocks
Novartis ( NVS ) recently
announced encouraging data on diabetes drug Galvus (vildagliptin)
from a large multi-center randomized trial, INTERVAL study
(n=278). The 24-week study evaluated... Read >>
Obesity Data on Novo Nordisk's Victoza - Analyst Blog
5/28/2013, 4:28 pm from Zacks.com in Investing, Business, Stocks
Novo Nordisk ( NVO ) recently
announced top-line data on Victoza (liraglutide) from a
double-blind phase IIIa study which was conducted to evaluate the
potential of Victoza to induce and... Read >>
Positive Data on Novo Nordisk's N9-GP - Analyst Blog
5/21/2013, 5:27 pm from Zacks.com in Investing, Business, Stocks
Novo Nordisk ( NVO ) recently
announced positive phase III data on its hemophilia B candidate,
N9-GP, from the paradigm 2 study. Paradigm 2 evaluated N9-GP, a long-acting FIX derivative,... Read >>
Novo Nordisk Rapidly Raising Dividend
5/14/2013, 5:49 pm from Investor's Business Daily in Personal Finance, Investing Ideas
DrugmakerNovo Nordisk ( NVO ) has boosted its
dividend sharply the past couple of years. The annual dividend was recently raised 29% to the equivalent of
about $3.11 a share for holders of... Read >>
Earnings and Sales Rise at Novo Nordisk - Analyst Blog
5/2/2013, 8:52 am from Zacks.com in Investing, Business, Earnings, Stocks
Novo Nordisk ( NVO ) reported first
quarter 2013 earnings of $1.94 per American Depository Receipt
(ADR), up 32.5% from the year-ago period. Revenues in the first
quarter of 2013... Read >>
Novo Nordisk and EMIS Modify Deal - Analyst Blog
5/1/2013, 4:47 pm from Zacks.com in Investing, Business, Stocks
Novo Nordisk A/S ( NVO ) and
Emisphere Technologies, Inc. ( EMIS ) recently
announced that they have modified their agreement for the
development and commercialization of oral... Read >>
Positive Data on Lilly Diabetes Candidate - Analyst Blog
4/18/2013, 3:17 pm from Zacks.com in Investing, Business, Stocks
Eli Lilly and Company ( LLY ) recently
announced top-line data on its type II diabetes candidate,
dulaglutide. The company said that dulaglutide met its primary
endpoint in two phase III... Read >>